Fennec Pharmaceuticals (FENC) Equity Average (2016 - 2025)
Historic Equity Average for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to -$6.0 million.
- Fennec Pharmaceuticals' Equity Average fell 8313.42% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 8313.42%. This contributed to the annual value of -$8.7 million for FY2024, which is 2327.53% down from last year.
- Latest data reveals that Fennec Pharmaceuticals reported Equity Average of -$6.0 million as of Q3 2025, which was down 8313.42% from -$6.7 million recorded in Q2 2025.
- In the past 5 years, Fennec Pharmaceuticals' Equity Average registered a high of $27.0 million during Q1 2021, and its lowest value of -$8.5 million during Q2 2023.
- Moreover, its 5-year median value for Equity Average was -$546750.0 (2023), whereas its average is $3.2 million.
- Its Equity Average has fluctuated over the past 5 years, first surged by 16555.37% in 2021, then plummeted by 437123.29% in 2024.
- Quarter analysis of 5 years shows Fennec Pharmaceuticals' Equity Average stood at $20.6 million in 2021, then crashed by 99.44% to $116500.0 in 2022, then plummeted by 975.97% to -$1.0 million in 2023, then plummeted by 441.06% to -$5.5 million in 2024, then fell by 8.26% to -$6.0 million in 2025.
- Its last three reported values are -$6.0 million in Q3 2025, -$6.7 million for Q2 2025, and -$5.9 million during Q1 2025.